Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 355

1.

Risk factors for disease progression in idiopathic pulmonary fibrosis.

Raghu G, Ley B, Brown KK, Cottin V, Gibson KF, Kaner RJ, Lederer DJ, Noble PW, Song JW, Wells AU, Whelan TP, Lynch DA, Humphries SM, Moreau E, Goodman K, Patterson SD, Smith V, Gong Q, Sundy JS, O'Riordan TG, Martinez FJ.

Thorax. 2019 Oct 14. pii: thoraxjnl-2019-213620. doi: 10.1136/thoraxjnl-2019-213620. [Epub ahead of print]

PMID:
31611341
2.

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.

Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, Richeldi L, Kolb M, Tetzlaff K, Stowasser S, Coeck C, Clerisme-Beaty E, Rosenstock B, Quaresma M, Haeufel T, Goeldner RG, Schlenker-Herceg R, Brown KK; INBUILD Trial Investigators.

N Engl J Med. 2019 Oct 31;381(18):1718-1727. doi: 10.1056/NEJMoa1908681. Epub 2019 Sep 29.

PMID:
31566307
3.

Modelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis: Optimising Trial Design.

Santermans E, Ford P, Kreuter M, Verbruggen N, Meyvisch P, Wuyts WA, Brown KK, Lederer DJ, Byrne AJ, Molyneaux PL, Sivananthan A, Moor CC, Maher TM, Wijsenbeek M.

Adv Ther. 2019 Sep 29. doi: 10.1007/s12325-019-01093-3. [Epub ahead of print]

PMID:
31565781
4.

MUC5B variant is associated with visually and quantitatively detected preclinical pulmonary fibrosis.

Mathai SK, Humphries S, Kropski JA, Blackwell TS, Powers J, Walts AD, Markin C, Woodward J, Chung JH, Brown KK, Steele MP, Loyd JE, Schwarz MI, Fingerlin T, Yang IV, Lynch DA, Schwartz DA.

Thorax. 2019 Sep 26. pii: thoraxjnl-2018-212430. doi: 10.1136/thoraxjnl-2018-212430. [Epub ahead of print]

PMID:
31558622
5.

Robotic direct reading device with spatial, temporal, and PID sensors for laboratory VOC exposure assessment.

Brown KK, Norton AE, Neu DT, Shaw PB.

J Occup Environ Hyg. 2019 Nov;16(11):717-726. doi: 10.1080/15459624.2019.1657580. Epub 2019 Sep 18.

PMID:
31532332
6.

Which Biopsy to Diagnose Interstitial Lung Disease? A Call for Evidence and Unity.

Richeldi L, Cottin V, Brown KK, Flaherty KR, Johannson KA, Travis WD, Collard HR.

Am J Respir Crit Care Med. 2019 Oct 1;200(7):941-942. doi: 10.1164/rccm.201905-0932LE. No abstract available.

7.

Acute exacerbations of fibrotic interstitial lung diseases.

Suzuki A, Kondoh Y, Brown KK, Johkoh T, Kataoka K, Fukuoka J, Kimura T, Matsuda T, Yokoyama T, Fukihara J, Ando M, Tanaka T, Hashimoto N, Sakamoto K, Hasegawa Y.

Respirology. 2019 Aug 19. doi: 10.1111/resp.13682. [Epub ahead of print]

PMID:
31426125
8.

Lung Hyperlucency: A Clinical-Radiologic Algorithmic Approach to Diagnosis.

Cherian SV, Girvin F, Naidich DP, Machnicki S, Brown KK, Ryu JH, Gupta N, Mehta V, Estrada-Y-Martin RM, Narasimhan M, Oks M, Raoof S.

Chest. 2019 Jul 26. pii: S0012-3692(19)31381-9. doi: 10.1016/j.chest.2019.06.037. [Epub ahead of print]

PMID:
31356811
9.

Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis.

Walsh SLF, Lederer DJ, Ryerson CJ, Kolb M, Maher TM, Nusser R, Poletti V, Richeldi L, Vancheri C, Wilsher ML, Antoniou KM, Behr J, Bendstrup E, Brown KK, Corte TJ, Cottin V, Crestani B, Flaherty KR, Glaspole IN, Grutters J, Inoue Y, Kondoh Y, Kreuter M, Johannson KA, Ley B, Martinez FJ, Molina-Molina M, Morais A, Nunes H, Raghu G, Selman M, Spagnolo P, Taniguchi H, Tomassetti S, Valeyre D, Wijsenbeek M, Wuyts WA, Wells AU.

Am J Respir Crit Care Med. 2019 Nov 1;200(9):1146-1153. doi: 10.1164/rccm.201903-0493OC.

10.

Corrigendum: Loss of LDAH associated with prostate cancer and hearing loss.

Currall BB, Chen M, Sallari RC, Cotter M, Wong KE, Robertson NG, Penney KL, Lunardi A, Reschke M, Hickox AE, Yin Y, Wong GT, Fung J, Brown KK, Williamson RE, Sinnott-Armstrong NA, Kammin T, Ivanov A, Zepeda-Mendoza CJ, Shen J, Quade BJ, Signoretti S, Arnos KS, Banks AS, Patsopoulos N, Liberman MC, Kellis M, Pandolfi PP, Morton CC.

Hum Mol Genet. 2019 May 15;28(10):1753-1754. doi: 10.1093/hmg/ddz036. No abstract available.

11.

Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2).

Maher TM, Kreuter M, Lederer DJ, Brown KK, Wuyts W, Verbruggen N, Stutvoet S, Fieuw A, Ford P, Abi-Saab W, Wijsenbeek M.

BMJ Open Respir Res. 2019 May 21;6(1):e000422. doi: 10.1136/bmjresp-2019-000422. eCollection 2019.

12.

Reply to Hall et al.: Hypersensitivity Pneumonitis Mortality by Industry and Occupation.

Fernández Pérez ER, Sprunger D, Ratanawatkul P, Maier LA, Huie TJ, Swigris JJ, Solomon JJ, Mohning M, Keith RC, Brown KK.

Am J Respir Crit Care Med. 2019 Aug 15;200(4):518-519. doi: 10.1164/rccm.201904-0876LE. No abstract available.

13.

Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis.

Moore C, Blumhagen RZ, Yang IV, Walts A, Powers J, Walker T, Bishop M, Russell P, Vestal B, Cardwell J, Markin CR, Mathai SK, Schwarz MI, Steele MP, Lee J, Brown KK, Loyd JE, Crapo JD, Silverman EK, Cho MH, James JA, Guthridge JM, Cogan JD, Kropski JA, Swigris JJ, Bair C, Kim DS, Ji W, Kim H, Song JW, Maier LA, Pacheco KA, Hirani N, Poon AS, Li F, Jenkins RG, Braybrooke R, Saini G, Maher TM, Molyneaux PL, Saunders P, Zhang Y, Gibson KF, Kass DJ, Rojas M, Sembrat J, Wolters PJ, Collard HR, Sundy JS, O'Riordan T, Strek ME, Noth I, Ma SF, Porteous MK, Kreider ME, Patel NB, Inoue Y, Hirose M, Arai T, Akagawa S, Eickelberg O, Fernandez IE, Behr J, Mogulkoc N, Corte TJ, Glaspole I, Tomassetti S, Ravaglia C, Poletti V, Crestani B, Borie R, Kannengiesser C, Parfrey H, Fiddler C, Rassl D, Molina-Molina M, Machahua C, Worboys AM, Gudmundsson G, Isaksson HJ, Lederer DJ, Podolanczuk AJ, Montesi SB, Bendstrup E, Danchel V, Selman M, Pardo A, Henry MT, Keane MP, Doran P, Vašáková M, Sterclova M, Ryerson CJ, Wilcox PG, Okamoto T, Furusawa H, Miyazaki Y, Laurent G, Baltic S, Prele C, Moodley Y, Shea BS, Ohta K, Suzukawa M, Narumoto O, Nathan SD, Venuto DC, Woldehanna ML, Kokturk N, de Andrade JA, Luckhardt T, Kulkarni T, Bonella F, Donnelly SC, McElroy A, Armstong ME, Aranda A, Carbone RG, Puppo F, Beckman KB, Nickerson DA, Fingerlin TE, Schwartz DA.

Am J Respir Crit Care Med. 2019 Jul 15;200(2):199-208. doi: 10.1164/rccm.201810-1891OC.

14.

The Fibrosis Across Organs Symposium: A Roadmap for Future Research Priorities.

Roman J, Barnes TR, Kervitsky DJ, Cosgrove GP, Doherty DE, Tager AM, Richeldi L, White ES, Brenner DA, Schnapp LM, Hewitson TD, Jugdutt BI, McKinsey TA, Tosi JD, Crane S, Brown KK; Fibrosis Across Organs Symposium Working Group.

Am J Med Sci. 2019 May;357(5):405-410. doi: 10.1016/j.amjms.2019.02.014. No abstract available.

15.

Idiopathic Pulmonary Fibrosis: Epidemiology, Diagnosis andOutcomes.

Wakwaya Y, Brown KK.

Am J Med Sci. 2019 May;357(5):359-369. doi: 10.1016/j.amjms.2019.02.013. Epub 2019 Feb 15.

PMID:
31010461
16.

Use of a molecular classifier to identify usual interstitial pneumonia in conventional transbronchial lung biopsy samples: a prospective validation study.

Raghu G, Flaherty KR, Lederer DJ, Lynch DA, Colby TV, Myers JL, Groshong SD, Larsen BT, Chung JH, Steele MP, Benzaquen S, Calero K, Case AH, Criner GJ, Nathan SD, Rai NS, Ramaswamy M, Hagmeyer L, Davis JR, Gauhar UA, Pankratz DG, Choi Y, Huang J, Walsh PS, Neville H, Lofaro LR, Barth NM, Kennedy GC, Brown KK, Martinez FJ.

Lancet Respir Med. 2019 Jun;7(6):487-496. doi: 10.1016/S2213-2600(19)30059-1. Epub 2019 Apr 1.

PMID:
30948346
17.

Pulmonary fibrosis: "idiopathic" is not "cryptogenic".

Wells AU, Brown KK, Flaherty KR, Kolb M, Thannickal VJ; IPF Consensus Working Group; IPF Consensus Working Group:.

Eur Respir J. 2019 Mar 18;53(3). pii: 1900400. doi: 10.1183/13993003.00400-2019. Print 2019 Mar. No abstract available.

PMID:
30886028
18.

Research in Pulmonary Fibrosis Across Species: Unleashing Discovery Through Comparative Biology.

Barnes T, Brown KK, Corcoran B, Glassberg MK, Kervitsky DJ, Limper AH, McGuire K, Williams K, Roman J; Comparative Biology of Pulmonary Fibrosis Group.

Am J Med Sci. 2019 May;357(5):399-404. doi: 10.1016/j.amjms.2019.02.005. Epub 2019 Feb 11. No abstract available.

19.

Analysis of the MILES cohort reveals determinants of disease progression and treatment response in lymphangioleiomyomatosis.

Gupta N, Lee HS, Young LR, Strange C, Moss J, Singer LG, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch JP 3rd, Goldberg HJ, Downey GP, Taveira-DaSilva AM, Krischer JP, Setchell K, Trapnell BC, Inoue Y, McCormack FX; NIH Rare Lung Disease Consortium.

Eur Respir J. 2019 Apr 4;53(4). pii: 1802066. doi: 10.1183/13993003.02066-2018. Print 2019 Apr.

PMID:
30846465
20.

Increasing Hypersensitivity Pneumonitis-related Mortality in the United States from 1988 to 2016.

Fernández Pérez ER, Sprunger DB, Ratanawatkul P, Maier LA, Huie TJ, Swigris JJ, Solomon JJ, Mohning MP, Keith RC, Brown KK.

Am J Respir Crit Care Med. 2019 May 15;199(10):1284-1287. doi: 10.1164/rccm.201807-1258LE. No abstract available.

PMID:
30768910
21.

Idiopathic interstitial pneumonia or idiopathic interstitial pneumonitis: what's in a name?

Wells AU, Brown KK, Flaherty KR, Kolb M, Thannickal VJ; IPF Consensus Working Group; IPF Consensus Working Group:.

Eur Respir J. 2019 Feb 14;53(2). pii: 1801939. doi: 10.1183/13993003.01939-2018. Print 2019 Feb. No abstract available.

PMID:
30765483
22.

Lung function outcomes in the INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosis.

Brown KK, Flaherty KR, Cottin V, Raghu G, Inoue Y, Azuma A, Huggins JT, Richeldi L, Stowasser S, Stansen W, Schlenker-Herceg R, Maher TM, Wells AU.

Respir Med. 2019 Jan;146:42-48. doi: 10.1016/j.rmed.2018.11.012. Epub 2018 Nov 19.

PMID:
30665517
23.

Interstitial lung disease associated with systemic sclerosis (SSc-ILD).

Cottin V, Brown KK.

Respir Res. 2019 Jan 18;20(1):13. doi: 10.1186/s12931-019-0980-7. Review.

24.

Characterization of the Src-regulated kinome identifies SGK1 as a key mediator of Src-induced transformation.

Ma X, Zhang L, Song J, Nguyen E, Lee RS, Rodgers SJ, Li F, Huang C, Schittenhelm RB, Chan H, Chheang C, Wu J, Brown KK, Mitchell CA, Simpson KJ, Daly RJ.

Nat Commun. 2019 Jan 17;10(1):296. doi: 10.1038/s41467-018-08154-1.

25.

Proceedings of the American College of Rheumatology/Association of Physicians of Great Britain and Ireland Connective Tissue Disease-Associated Interstitial Lung Disease Summit: A Multidisciplinary Approach to Address Challenges and Opportunities.

Fischer A, Strek ME, Cottin V, Dellaripa PF, Bernstein EJ, Brown KK, Danoff SK, Distler O, Hirani N, Jones KD, Khanna D, Lee JS, Lynch DA, Maher TM, Millar AB, Raghu G, Silver RM, Steen VD, Volkmann ER, Mullan RH, O'Dwyer DN, Donnelly SC.

QJM. 2019 Feb 1;112(2):81-93. doi: 10.1093/qjmed/hcy272. No abstract available.

PMID:
30605544
26.

Proceedings of the American College of Rheumatology/Association of Physicians of Great Britain and Ireland Connective Tissue Disease-Associated Interstitial Lung Disease Summit: A Multidisciplinary Approach to Address Challenges and Opportunities.

Fischer A, Strek ME, Cottin V, Dellaripa PF, Bernstein EJ, Brown KK, Danoff SK, Distler O, Hirani N, Jones KD, Khanna D, Lee JS, Lynch DA, Maher TM, Millar AB, Raghu G, Silver RM, Steen VD, Volkmann ER, Mullan RH, O'Dwyer DN, Donnelly SC.

Arthritis Rheumatol. 2019 Feb;71(2):182-195. doi: 10.1002/art.40769. Epub 2019 Jan 3. No abstract available.

PMID:
30604506
27.

Patients' perceptions and patient-reported outcomes in progressive-fibrosing interstitial lung diseases.

Swigris JJ, Brown KK, Abdulqawi R, Buch K, Dilling DF, Koschel D, Thavarajah K, Tomic R, Inoue Y.

Eur Respir Rev. 2018 Dec 21;27(150). pii: 180075. doi: 10.1183/16000617.0075-2018. Print 2018 Dec 31. Review.

28.

Yap regulates glucose utilization and sustains nucleotide synthesis to enable organ growth.

Cox AG, Tsomides A, Yimlamai D, Hwang KL, Miesfeld J, Galli GG, Fowl BH, Fort M, Ma KY, Sullivan MR, Hosios AM, Snay E, Yuan M, Brown KK, Lien EC, Chhangawala S, Steinhauser ML, Asara JM, Houvras Y, Link B, Vander Heiden MG, Camargo FD, Goessling W.

EMBO J. 2018 Nov 15;37(22). pii: e100294. doi: 10.15252/embj.2018100294. Epub 2018 Oct 22.

PMID:
30348863
29.

Loss of LDAH associated with prostate cancer and hearing loss.

Currall BB, Chen M, Sallari RC, Cotter M, Wong KE, Robertson NG, Penney KL, Lunardi A, Reschke M, Hickox AE, Yin Y, Wong GT, Fung J, Brown KK, Williamson RE, Sinnott-Armstrong NA, Kammin T, Ivanov A, Zepeda-Mendoza CJ, Shen J, Quade BJ, Signoretti S, Arnos KS, Banks AS, Patsopoulos N, Liberman MC, Kellis M, Pandolfi PP, Morton CC.

Hum Mol Genet. 2018 Dec 15;27(24):4194-4203. doi: 10.1093/hmg/ddy310. Erratum in: Hum Mol Genet. 2019 May 15;28(10):1753-1754.

PMID:
30169630
30.

Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.

Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, Behr J, Cottin V, Danoff SK, Morell F, Flaherty KR, Wells A, Martinez FJ, Azuma A, Bice TJ, Bouros D, Brown KK, Collard HR, Duggal A, Galvin L, Inoue Y, Jenkins RG, Johkoh T, Kazerooni EA, Kitaichi M, Knight SL, Mansour G, Nicholson AG, Pipavath SNJ, Buendía-Roldán I, Selman M, Travis WD, Walsh S, Wilson KC; American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society.

Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44-e68. doi: 10.1164/rccm.201807-1255ST.

PMID:
30168753
31.

Quantitative high-resolution computed tomography fibrosis score: performance characteristics in idiopathic pulmonary fibrosis.

Humphries SM, Swigris JJ, Brown KK, Strand M, Gong Q, Sundy JS, Raghu G, Schwarz MI, Flaherty KR, Sood R, O'Riordan TG, Lynch DA.

Eur Respir J. 2018 Sep 17;52(3). pii: 1801384. doi: 10.1183/13993003.01384-2018. Print 2018 Sep.

PMID:
30139770
32.

Biocatalytic Synthesis of Chiral N-Functionalized Amino Acids.

Hyslop JF, Lovelock SL, Sutton PW, Brown KK, Watson AJB, Roiban GD.

Angew Chem Int Ed Engl. 2018 Oct 15;57(42):13821-13824. doi: 10.1002/anie.201806893. Epub 2018 Sep 21.

PMID:
30138551
33.

Approaches to target tractability assessment - a practical perspective.

Brown KK, Hann MM, Lakdawala AS, Santos R, Thomas PJ, Todd K.

Medchemcomm. 2018 Feb 14;9(4):606-613. doi: 10.1039/c7md00633k. eCollection 2018 Apr 1. Review.

34.

Reducing protein oxidation reverses lung fibrosis.

Anathy V, Lahue KG, Chapman DG, Chia SB, Casey DT, Aboushousha R, van der Velden JLJ, Elko E, Hoffman SM, McMillan DH, Jones JT, Nolin JD, Abdalla S, Schneider R, Seward DJ, Roberson EC, Liptak MD, Cousins ME, Butnor KJ, Taatjes DJ, Budd RC, Irvin CG, Ho YS, Hakem R, Brown KK, Matsui R, Bachschmid MM, Gomez JL, Kaminski N, van der Vliet A, Janssen-Heininger YMW.

Nat Med. 2018 Aug;24(8):1128-1135. doi: 10.1038/s41591-018-0090-y. Epub 2018 Jul 9.

35.

Computed Tomographic Biomarkers in Idiopathic Pulmonary Fibrosis. The Future of Quantitative Analysis.

Wu X, Kim GH, Salisbury ML, Barber D, Bartholmai BJ, Brown KK, Conoscenti CS, De Backer J, Flaherty KR, Gruden JF, Hoffman EA, Humphries SM, Jacob J, Maher TM, Raghu G, Richeldi L, Ross BD, Schlenker-Herceg R, Sverzellati N, Wells AU, Martinez FJ, Lynch DA, Goldin J, Walsh SLF.

Am J Respir Crit Care Med. 2019 Jan 1;199(1):12-21. doi: 10.1164/rccm.201803-0444PP. No abstract available.

36.

The NHLBI LAM Registry: Prognostic Physiologic and Radiologic Biomarkers Emerge From a 15-Year Prospective Longitudinal Analysis.

Gupta N, Lee HS, Ryu JH, Taveira-DaSilva AM, Beck GJ, Lee JC, McCarthy K, Finlay GA, Brown KK, Ruoss SJ, Avila NA, Moss J, McCormack FX; NHLBI LAM Registry Group.

Chest. 2019 Feb;155(2):288-296. doi: 10.1016/j.chest.2018.06.016. Epub 2018 Jun 22.

PMID:
29940164
37.

Psychometric properties of the St George's Respiratory Questionnaire in patients with idiopathic pulmonary fibrosis: insights from the INPULSIS trials.

Swigris JJ, Wilson H, Esser D, Conoscenti CS, Stansen W, Kline Leidy N, Brown KK.

BMJ Open Respir Res. 2018 May 18;5(1):e000278. doi: 10.1136/bmjresp-2018-000278. eCollection 2018.

38.

Tumor immune evasion arises through loss of TNF sensitivity.

Kearney CJ, Vervoort SJ, Hogg SJ, Ramsbottom KM, Freeman AJ, Lalaoui N, Pijpers L, Michie J, Brown KK, Knight DA, Sutton V, Beavis PA, Voskoboinik I, Darcy PK, Silke J, Trapani JA, Johnstone RW, Oliaro J.

Sci Immunol. 2018 May 18;3(23). pii: eaar3451. doi: 10.1126/sciimmunol.aar3451.

PMID:
29776993
39.

What's in a name? That which we call IPF, by any other name would act the same.

Wells AU, Brown KK, Flaherty KR, Kolb M, Thannickal VJ; IPF Consensus Working Group.

Eur Respir J. 2018 May 17;51(5). pii: 1800692. doi: 10.1183/13993003.00692-2018. Print 2018 May. Review.

40.

The relationship between complement C3 expression and the MUC5B genotype in pulmonary fibrosis.

Okamoto T, Mathai SK, Hennessy CE, Hancock LA, Walts AD, Stefanski AL, Brown KK, Lynch DA, Cosgrove GP, Groshong SD, Cool CD, Schwarz MI, Banda NK, Thurman JM, Yang IV, Holers VM, Schwartz DA.

Am J Physiol Lung Cell Mol Physiol. 2018 Jul 1;315(1):L1-L10. doi: 10.1152/ajplung.00395.2017. Epub 2018 Mar 22.

41.

Cavitary Lung Diseases: A Clinical-Radiologic Algorithmic Approach.

Gafoor K, Patel S, Girvin F, Gupta N, Naidich D, Machnicki S, Brown KK, Mehta A, Husta B, Ryu JH, Sarosi GA, Franquet T, Verschakelen J, Johkoh T, Travis W, Raoof S.

Chest. 2018 Jun;153(6):1443-1465. doi: 10.1016/j.chest.2018.02.026. Epub 2018 Mar 6. Review.

PMID:
29518379
42.

Youth empowerment implementation project evaluation results: A program designed to improve the health and well-being of low-income African-American adolescents.

Lewis RK, Lee FA, Brown KK, LoCurto J, Stowell D, Maryman J, Lovelady T, Williams G, Morris DM, McNair T.

J Prev Interv Community. 2018 Jan-Mar;46(1):28-42. doi: 10.1080/10852352.2018.1385954.

PMID:
29281596
43.

Is Timing of Enrollment Associated with Birth Outcomes? Findings from a Healthy Start Program in Kansas.

Brown KK, Johnson C, Spainhower M, Phillips NF, Maryman J.

Matern Child Health J. 2017 Dec;21(Suppl 1):25-31. doi: 10.1007/s10995-017-2405-x.

44.

Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper.

Lynch DA, Sverzellati N, Travis WD, Brown KK, Colby TV, Galvin JR, Goldin JG, Hansell DM, Inoue Y, Johkoh T, Nicholson AG, Knight SL, Raoof S, Richeldi L, Ryerson CJ, Ryu JH, Wells AU.

Lancet Respir Med. 2018 Feb;6(2):138-153. doi: 10.1016/S2213-2600(17)30433-2. Epub 2017 Nov 15. Review.

45.

Reply: Improving Care for Patients with Interstitial Lung Disease, Using Machine Learning, Requires Transparency and Reproducibility.

Kennedy GC, Barth NM, Walsh PS, Huang J, Pankratz DG, Choi Y, Fedorowicz GM, Anderson JD, Raghu G, Martinez FJ, Colby TV, Lynch DA, Brown KK, Groshong SD, Myers JL, Flaherty KR, Steele MP.

Ann Am Thorac Soc. 2017 Dec;14(12):1864-1865. doi: 10.1513/AnnalsATS.201708-654LE. No abstract available.

PMID:
29058451
46.

Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease.

Flaherty KR, Brown KK, Wells AU, Clerisme-Beaty E, Collard HR, Cottin V, Devaraj A, Inoue Y, Le Maulf F, Richeldi L, Schmidt H, Walsh S, Mezzanotte W, Schlenker-Herceg R.

BMJ Open Respir Res. 2017 Sep 17;4(1):e000212. doi: 10.1136/bmjresp-2017-000212. eCollection 2017.

47.

Recent lessons learned in the management of acute exacerbation of idiopathic pulmonary fibrosis.

Kondoh Y, Cottin V, Brown KK.

Eur Respir Rev. 2017 Sep 27;26(145). pii: 170050. doi: 10.1183/16000617.0050-2017. Print 2017 Sep 30. Review. Erratum in: Eur Respir Rev. 2018 Apr 13;27(148):.

48.

Cutaneous eruption associated with Streptococcus dysgalactiae (group C Streptococcus) bacteremia.

Ashchyan HJ, Brown KK.

JAAD Case Rep. 2017 Aug 12;3(5):373-375. doi: 10.1016/j.jdcr.2017.04.004. eCollection 2017 Sep. No abstract available.

49.

Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™).

Distler O, Brown KK, Distler JHW, Assassi S, Maher TM, Cottin V, Varga J, Coeck C, Gahlemann M, Sauter W, Schmidt H, Highland KB; SENSCIS™ trial investigators.

Clin Exp Rheumatol. 2017 Sep-Oct;35 Suppl 106(4):75-81. Epub 2017 Jun 29.

50.

Usual Interstitial Pneumonia Can Be Detected in Transbronchial Biopsies Using Machine Learning.

Pankratz DG, Choi Y, Imtiaz U, Fedorowicz GM, Anderson JD, Colby TV, Myers JL, Lynch DA, Brown KK, Flaherty KR, Steele MP, Groshong SD, Raghu G, Barth NM, Walsh PS, Huang J, Kennedy GC, Martinez FJ.

Ann Am Thorac Soc. 2017 Nov;14(11):1646-1654. doi: 10.1513/AnnalsATS.201612-947OC.

PMID:
28640655

Supplemental Content

Loading ...
Support Center